Identification of deprescribing opportunities for patients with diabetes and dementia discharged to a nursing home using a mortality prognostic index

  • Ammar Kayyali
  • Sarah E. PetiteEmail author
Short Communication



The prevalence of diabetes mellitus in elderly nursing home residents ranges from 25% to 34%. Glycemic goals for this patient population differ from those for the general population. Polypharmacy is a common issue in nursing home residents and is associated with significant complications. Deprescribing is one method to minimize polypharmacy. Deprescribing opportunities are frequently identified using a list of inappropriate medications. Use of a mortality prognostic index to identify deprescribing opportunities has not been studied in any patient population.


This was a noninterventional, retrospective, single-center cohort study at a 320-bed academic medical center. A total of 147 patients aged ≥ 65 years with dementia and type 2 diabetes mellitus receiving antihyperglycemic therapy during hospital admission were included. Life expectancy was calculated using the Mitchell Index. Opportunities for deprescribing were identified using glycated hemoglobin (HbA1c) levels and Mitchell Index scores. Patients were subcategorized into three groups based on their HbA1c (< 7%, 7–8%, and > 8%), and differences in life expectancy and functional status were determined.


In total, 106 patients (72%) were eligible for antihyperglycemic therapy deprescribing. The median HbA1c was 6.9% in the entire patient population. All three groups of patients had a high Mitchell Index score of 13.6 for HbA1c < 7%, 14.2 for HbA1c 7–8%, and 13.7 for HbA1c > 8%. The Mitchell Index scores estimated a 6-month mortality rate of at least 28% in this cohort. No differences in functional status or comorbidities were observed between HbA1c groups.


The 30-day mortality rates were higher than the predicted mortality rate in this patient population, indicating significant opportunities for deprescribing. Use of a mortality prognostic index, such as the Mitchell Index, for elderly nursing home residents with dementia can be considered to guide deprescribing.



The authors acknowledge the following students for assistance with data collection on this project: Moriah Muscaro, MD candidate 2019; Areej Usmani, MD candidate 2020; and Madison Ratycz, MD candidate 2020.

Compliance with ethical standards

Conflict of interest

Ammar Kayyali and Sarah E. Petite have no have no conflicts of interest that are directly relevant to the content of this article.


No sources of funding were used to conduct this study or prepare this manuscript.


  1. 1.
    Estimates of diabetes and its burden in the United States. National Diabetes Statistics Report. 2017. Accessed 2 Oct 2019
  2. 2.
    Munshi MN, Florez H, Huang ES, et al. Management of diabetes in long-term care and skilled nursing facilities: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(2):308–18.CrossRefGoogle Scholar
  3. 3.
    Farrell B, Black C, Thompson W, et al. Deprescribing antihyperglycemic agents in older persons: evidence-based clinical practice guideline. Can Fam Phys. 2017;63(11):832–43.Google Scholar
  4. 4.
    American Diabetes Association. 12. Older adults: standards of medical care in diabetes–2019. Diabetes Care. 2019;42(Suppl 1):S139–47.CrossRefGoogle Scholar
  5. 5.
    Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650–64.CrossRefGoogle Scholar
  6. 6.
    Cherubini A, Corsonello A, Lattanzio F. Polypharmacy in nursing home residents: what is the way forward? J Am Med Dir Assoc. 2016;17(1):4–6.CrossRefGoogle Scholar
  7. 7.
    Payne RA, Avery AJ. Polypharmacy: one of the greatest prescribing challenges in general practice. Br J Gen Pract. 2011;61(583):83–4.CrossRefGoogle Scholar
  8. 8.
    Dwyer LL, Han B, Woodwell DA, et al. Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. Am J Geriatr Pharmacother. 2010;8(1):63–72.CrossRefGoogle Scholar
  9. 9.
    Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170(18):1648–54.CrossRefGoogle Scholar
  10. 10.
    Gadsby R, Galloway M, Barker P, et al. Prescribed medicines for elderly frail people with diabetes resident in nursing homes-issues of polypharmacy and medication costs. Diabet Med. 2012;29(1):136–9.CrossRefGoogle Scholar
  11. 11.
    Page AT, Clifford RM, Potter K, et al. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623.CrossRefGoogle Scholar
  12. 12.
    Reeve E, Gnjidic D, Long J, et al. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68.CrossRefGoogle Scholar
  13. 13.
    Thillainadesan J, Gnjidic D, Green S, et al. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35(4):303–19.CrossRefGoogle Scholar
  14. 14.
    Black CD, Thompson W, Welch V, et al. Lack of evidence to guide deprescribing of antihyperglycemics: a systematic review. Diabetes Ther. 2017;8(1):23–31.CrossRefGoogle Scholar
  15. 15.
    Mitchell SL, Miller SC, Teno JM, et al. Prediction of 6-month survival of nursing home residents with advanced dementia using ADEPT vs hospice eligibility guidelines. JAMA. 2010;304(17):1929–35.CrossRefGoogle Scholar
  16. 16.
    Seidu S, Kunutsor SK, Topsever P, et al. Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes. Diabetes Obes Metab. 2019;21(7):1668–79.CrossRefGoogle Scholar
  17. 17.
    Aspinall SL, Zhao X, Good CB, et al. Intervention to decrease glyburide use in elderly patients with renal insufficiency. Am J Geriatr Pharmacother. 2011;9(1):58–68.CrossRefGoogle Scholar
  18. 18.
    Sjoblom P, Tengblad A, Lofgren UB, et al. Can diabetes medication be reduced in elderly patients? An observational study of diabetes drug withdrawal in nursing home patients with tight glycaemic control. Diabetes Res Clin Pract. 2008;82(2):197–202.CrossRefGoogle Scholar
  19. 19.
    Lipska KJ, Wang Y, Kosiborod M, et al. Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes. Circ Cardiovasc Qual Outcomes. 2010;3(3):236–42.CrossRefGoogle Scholar
  20. 20.
    Luymes CH, van der Kleij RM, Poortvliet RK, et al. Deprescribing potentially inappropriate preventive cardiovascular medication: barriers and enablers for patients and general practitioners. Ann Pharmacother. 2016;50(6):446–54.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of Toledo Medical CenterToledoUSA
  2. 2.University of Toledo College of Pharmacy and Pharmaceutical SciencesToledoUSA

Personalised recommendations